Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine in uterine cancer surgery
NCT02896413Completed
- Sponsor
- Yonsei University
- Start
- Jun 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, triple-blind trial of dexmedetomidine in immunosuppression (2 arms), sponsored by Yonsei University. Primary endpoint: Natural killer cell cytotoxicity. Started Jun 2016; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
immunosuppression
Beyond the preview
Go deeper on NCT02896413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02896413.